Silo Pharma, Inc. announced the closing of its registered direct offering on October 1, 2025, raising gross proceeds of approximately $2.5 million from the sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. The offering was priced at‑the‑market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. The transaction was conducted under a shelf registration statement on Form S‑3, effective January 30, 2024, and included the issuance of unregistered warrants for up to 2,857,143 shares at an exercise price of $0.75, immediately exercisable upon issuance. The net proceeds from the offering will be used for working capital and general corporate purposes, supporting Silo’s developmental‑stage biopharmaceutical pipeline and its emerging cryptocurrency treasury strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.